Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PDS Biotechnology CorpPDSB · Entity 7939 | Interim CFO | December 08, 2020 | December 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PDS Biotechnology Corp
Report date December 08, 2020 · Filed December 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2030-12-08 | Direct | 50,000 |
Reported balance
After 2020-12-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-08 · Grant · Acquired 50,000 · Balance 50,000 F1: The option is fully vested and immediately exercisable as of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and immediately exercisable as of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 08, 2020 Filed Dec 9, 2020 16:13 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001140361-20-027866 · form4.xml · derivative · entry 1 King Michael N. · CIK 0001816304 · Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: The option is fully vested and immediately exercisable as of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.